Effect of acitretin on serum biomarkers levels in patients with psoriasis

Abstract EN

Psoriasis is a multifactorial, chronic, inflammatory skin disease of unknown etiology, associated with cytokines and adipokines serum levels changes that may influence disease pathogenesis.

To determine the effect of acitretin on serum IL-10, IL-23, adiponectin, Zn, Mg and copper levels in psoriasis patients.

A case control study that include 50 psoriasis patients, conducted in Tikrit Teaching Hospital.

They received acitretin orally for 4 weeks duration course.

IL-10, IL-23, adiponectin, Zn, Cu and Mg in serum for all patients determined at the time of enrollement in the study and after 4 weeks of treatment with the drug.

Acitretin reduced the mean PASI in 20 psoriatic patients from 20.97 before receiving treatment to 1.22 after receiving treatment (P = 0.000).

In addition, the mean serum levels for IL-10 reduced significantly (P = 0.000) from (6.01±4.17) pg/ml before treatment to (1.85 ± 0.54) pg/ml after treatment.

Furthermore, Acitretin reduced the mean serum level for IL-23 from (72.08 ± 34.14) pg / ml pre-treatment to (66.1± 20.3) pg / ml, posttreatment (P = 0.423).

The mean serum levels of adiponectin in therapeutic group was lower (6.97 ± 3.06) μg / ml than that of baseline value (8.9 ± 3.96) μg/ml, but this result was statistically not significant (p = 0.114).

The mean serum levels of Zinc and copper in therapeutic group was lower than baseline value, but the difference was statistically not significant (p > 0.05).